Clinical trial

Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)

NCT07744698

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-07-24

PhasePHASE4

Study timeline

Study start (actual)2026-07-24Date precision: day

Registry last updated2026-08-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Squamous Non-Small Cell Lung Cancer sqNSCLCunresolved

Extensive-stage Small Cell Lung Cancer (ES-SCLC)unresolved

Interventions

Paclitaxel Oral SolutionDRUG

PD-1/PD-L1 inhibitor (eg. Tislelizumab)DRUG

Sponsors & collaborators

Anhui Provincial Cancer Hospitallead sponsor

Mapped research locations

HefeiAnhui, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07744698 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.